Surrozen, Inc.
Surrozen, Inc. (SRZN) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
srzn · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Surrozen, Inc.You SRZN | $155M | N/A | — | — |
 Agenus Inc. AGEN | $135M | 811.87x | — | $0.00 |
 Atossa Therapeutics, Inc. ATOS | $39M | N/A | — | -$4.04 |
 Cognition Therapeutics, Inc. CGTX | $89M | N/A | — | -$0.32 |
 Greenwich LifeSciences, Inc. GLSI | $330M | N/A | — | -$1.43 |
 Immix Biopharma, Inc. IMMX | $435M | N/A | — | -$0.89 |
 Opus Genetics, Inc. IRD | $330M | N/A | — | -$0.08 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Surrozen, Inc. (SRZN) measures how much investors pay for each dollar of the company's trailing earnings. SRZN's current PE ratio of N/A is calculated by dividing its stock price of $20.69 by its TTM earnings per share of —.
Frequently asked questions
SRZN pe ratio · 6 questionsSRZN's current PE ratio is N/A as of 2026-06-09, based on a stock price of $20.69 and TTM EPS of —. Data sourced from Financial Modeling Prep via SRZN's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Surrozen, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09